Psoriasis. Psoriasis
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive a topical cream containing 5% recombinant epidermal growth factor, twice a day for a month. Intervention 2: Control group: the g
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Informed consent Mild to moderate psoriasis (all types) with active plaques on both body sides accessible for self product application Age 18-60 years
Exclusion criteria
Exclusion criteria: Systemic psoriasis treatment 3 months prior and during the study Local psoriasis treatment on the investigational sites in the last 30 days or during the study Known hypersensitivity or allergy to the EGF containing product and/or to Vaseline/10% salicylic acid History of malignant disease Other clinically relevant concomitant disease state Participation in another investigational drug study in the last 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure of Psoriasis Area and Severity Index (PASI). Timepoint: before intervention and 1. Method of measurement: Psoriasis Area and Severity Index (PASI) based on the standard. | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin quality. Timepoint: Before intervention and 1. Method of measurement: Ultrasound skin imaging. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammadamir Amirkhani
Tehran University of Medical Sciences
Outcome results
None listed